A new study by the University of South Wales and St. George Hospital in Sydney, Australia has found that a second cytoreductive surgery (CRS) increased median survival time for patients suffering from peritoneal mesothelioma. The study, published in the Journal of Surgical Oncology in July 2019, evaluated outcomes for 101 patients with peritoneal mesothelioma who underwent perioperative intraperitoneal chemotherapy (PIC) and cytoreduction surgery. Cytoreduction is a complex surgical procedure to remove tumors in patients with peritoneal mesothelioma. The procedure is complicated and can take between 10 and 12 hours.
Peritoneal Mesothelioma Study Results
The study findings are promising for mesothelioma patients: Peritoneal mesothelioma patients undergoing a second CRS/PIC treatment had a median overall survival rate of 92 months and a 5-year survival rate of 71.8 percent. Without second CRS/PIC treatment, survival rates for peritoneal mesothelioma are significantly lower, with a median overall survival rate of 60 months and a 5-year survival rate of 48 percent. According to the study authors:“The present large-cohort data highlights that CRS/PIC are effective and safe in providing long-term survival benefit.”The authors noted that outcomes were significantly better for female patients, perhaps due to reduced exposure to asbestos. Mesothelioma is an especially deadly form of cancer often caused by exposure to asbestos, a fibrous mineral largely outlawed in the United States since 1989. Peritoneal mesothelioma, which occurs in the abdomen, is less common than pleural mesothelioma, which occurs in the lungs.